# Dietary Insulinogenic Amino Acid Restriction Improves Glucose Metabolism in a Neonatal Piglet Model

**Authors:** Matthew W. Gorton, Parniyan Goodarzi, Xia Lei, Michael Anderson, Mohammad Habibi, Nedra Wilson, Adel Pezeshki

PMC · DOI: 10.3390/nu17101675 · 2025-05-15

## TL;DR

Restricting insulinogenic amino acids in neonatal piglets improves glucose metabolism and insulin sensitivity without affecting body weight.

## Contribution

This study demonstrates that dietary restriction of insulinogenic amino acids improves glucose metabolism and insulin sensitivity in a neonatal piglet model.

## Key findings

- IAA restriction improved glucose tolerance and reduced insulin resistance markers in piglets.
- R75 increased glucose transporter and glycolysis-related gene expression in liver and white adipose tissue.
- IAA restriction enhanced insulin signaling in skeletal muscle and increased FGF-21 signaling.

## Abstract

Background: Dietary consumption of insulinogenic amino acids (IAA) is known to contribute to the development of insulin resistance. It remains to be studied whether dietary IAA restriction improves glucose metabolism and insulin sensitivity and whether this improvement is related to alterations in glucose metabolism in peripheral tissues. The objective of this study was to examine the effect of IAA restriction on glucose metabolism in a piglet model. Methods: Following the acclimation period, thirty-two seven-day-old male piglets were randomly assigned into one of three groups for three weeks as follows (n = 10–11/group): (1) NR (control): basal diet without IAA restriction; (2) R50: basal diet with IAA restricted by 50%; (3) R75: basal diet with IAA restricted by 75%. IAA were alanine (Ala), arginine (Arg), isoleucine (Ile), leucine (Leu), lysine (Lys), threonine (Thr), phenylalanine (Phe), and valine (Val) as suggested by previous studies. Thermal images, body weight, and growth parameters were recorded weekly, oral glucose tolerance tests were performed on week 2 of the study, and blood and tissue samples were collected on week 3 after a meal test. Results: R75 improved glucose tolerance and, together with R50, reduced blood insulin concentration and homeostatic model assessment for insulin resistance (HOMA-IR) value, which is suggestive of improved insulin sensitivity following IAA restriction. R75 increased thermal radiation and decreased adipocyte number in white adipose tissue (WAT). R75 had a greater transcript of glucose transporter 1 (GLUT1), phosphofructokinase, liver type (PFKL), and pyruvate kinase, liver, and RBC (PKLR) in the liver and glucokinase (GCK) in WAT indicating a higher uptake of glucose in the liver and greater glycolysis in both liver and WAT. R75 increased the mRNA abundance of insulin receptor substrate 1 (IRS1) and protein kinase B (AKT1) in skeletal muscle suggestive of enhanced insulin signaling. Further, R75 had a higher mRNA of fibroblast growth factor 21 (FGF-21) in both the liver and hypothalamus and its upstream molecules such as activating transcription factor 4 (ATF4) and inhibin subunit beta E (INHBE) which may contribute to increased energy expenditure and improved glucose tolerance during IAA restriction. Conclusions: IAA restriction improves glucose tolerance and insulin sensitivity in piglets while not reducing body weight, likely through improved hepatic glycolysis and insulin signaling in skeletal muscle, and induced FGF-21 signaling in both the liver and hypothalamus.

## Linked entities

- **Genes:** SLC2A1 (solute carrier family 2 member 1) [NCBI Gene 6513], PFKL (phosphofructokinase, liver type) [NCBI Gene 5211], PKLR (pyruvate kinase L/R) [NCBI Gene 5313], GCK (glucokinase) [NCBI Gene 2645], IRS1 (insulin receptor substrate 1) [NCBI Gene 3667], AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207], FGF21 (fibroblast growth factor 21) [NCBI Gene 26291], ATF4 (activating transcription factor 4) [NCBI Gene 468], INHBE (inhibin subunit beta E) [NCBI Gene 83729]
- **Species:** Sus scrofa (taxon 9823)

## Full-text entities

- **Genes:** GCK (glucokinase) [NCBI Gene 2645] {aka FGQTL3, GK, GLK, HHF3, HK4, HKIV}, ATF4 (activating transcription factor 4) [NCBI Gene 468] {aka CREB-2, CREB2, TAXREB67, TXREB}, INHBE (inhibin subunit beta E) [NCBI Gene 83729], IRS1 (insulin receptor substrate 1) [NCBI Gene 3667] {aka HIRS-1}, PTK2B (protein tyrosine kinase 2 beta) [NCBI Gene 2185] {aka CADTK, CAKB, FADK2, FAK2, PKB, PTK}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, SLC2A1 (solute carrier family 2 member 1) [NCBI Gene 6513] {aka CSE, DYT17, DYT18, DYT9, EIG12, GLUT}, PFKL (phosphofructokinase, liver type) [NCBI Gene 5211] {aka ATP-PFK, PFK-B, PFK-L}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, PKLR (pyruvate kinase L/R) [NCBI Gene 5313] {aka CNSHA2, PK1, PKL, PKRL, RPK}, FGF21 (fibroblast growth factor 21) [NCBI Gene 26291]
- **Diseases:** insulin resistance (MESH:D007333)
- **Chemicals:** Thr (MESH:D013912), Val (MESH:D014633), Glucose (MESH:D005947), Ala (MESH:D000409), IAA (-), Leu (MESH:D007930), Arg (MESH:D001120), Lys (MESH:D008239), Ile (MESH:D007532), Phe (MESH:D010649)

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12114165/full.md

---
Source: https://tomesphere.com/paper/PMC12114165